Superior efficacy with the fixed-ratio combination of insulin degludec and liraglutide (IDegLira) compared with insulin degludec and liraglutide in insulin-naïve Japanese subjects with type 2 diabetes in a phase 3, open-label, randomised trial

Short running title: IDegLira in Japanese subjects with T2D

Authors: Kohei Kaku,[1] Eiichi Araki,[2] Yukio Tanizawa,[3] Bue Ross Agner,[4] Tomoyuki Nishida,[5] Mattis Ranthe[4] and Nobuya Inagaki[6]

Affiliations

1. Department of Internal Medicine, Kawasaki Medical School, Kurashiki, Japan

2. Department of Metabolic Medicine, Kumamoto University, Kumamoto, Japan

3. Yamaguchi University, Graduate School of Medicine, Ube, Japan

4. Novo Nordisk A/S, Søborg, Denmark

5. Novo Nordisk Pharma Ltd, Tokyo, Japan

6. Department of Diabetes, Endocrinology and Nutrition, Kyoto University Graduate School of Medicine, Kyoto, Japan

Corresponding author: Prof. Kohei Kaku. Department of Internal Medicine, Kawasaki Medical School, Kurashiki, Japan

Target journal: *Diabetes, Obesity and Metabolism*

Paper type: Original paper

Keywords: basal insulin, liraglutide; hypoglycaemia, type 2 diabetes, randomised trial

Abstract

Aims

To investigate the efficacy and safety of insulin degludec/liraglutide (IDegLira) compared with its individual components in Japanese subjects with type 2 diabetes (T2D) uncontrolled on an oral antidiabetic drug (OAD).

Materials and Methods

This 52-week, open-label, multicentre, treat-to-target trial randomised subjects (n=819) 1:1:1 to IDegLira, liraglutide 1.8 mg or degludec, as add-on to pre-trial OAD. Maximum IDegLira dose was 50 dose steps (50 U degludec/1.8 mg liraglutide); none for degludec; both titrated based on individual blood glucose measurements.

Results

After 52 weeks, HbA1c decreased by 26 mmol/mol with IDegLira vs 20 mmol/mol with degludec and liraglutide: estimated treatment differences were –6.91 mmol/mol [–8.18; –5.64]$_{95\%\ CI}$ and –5.30 mmol/mol [–6.58; –4.03]$_{95\%\ CI}$, confirming non-inferiority of IDegLira to degludec and superiority of IDegLira to liraglutide (p<0.0001 for both [primary endpoint]). Mean body weight change was 2.9, 4.1, –1.0 kg with IDegLira, degludec and liraglutide, respectively, showing superiority of IDegLira versus degludec (p=0.0001), but a significant difference in favour of liraglutide (p<0.0001). Rates of severe or blood glucose-confirmed hypoglycaemia for IDegLira were lower versus degludec (rate ratio: 0.48 [0.35; 0.68]$_{95\%CI}$, p<0.0001), but higher versus liraglutide (rate ratio: 37.58 [19.80; 71.31]$_{95\%CI}$, p<0.0001). Mean daily total insulin dose was lower with IDegLira (27.7U) versus degludec

(34.8U; p<0.0001). Overall adverse event (AE) rates were similar. In total, 34.9%, 22.9% and 41.8% of IDegLira-, degludec- and liraglutide-treated subjects experienced gastrointestinal AEs.

Conclusion

IDegLira was superior to degludec and liraglutide in terms of HbA1c reduction and superior to degludec in terms of body weight change and rates of hypoglycaemia in Japanese subjects with T2D.

Background

The prevalence of diabetes in Japan is expected to reach 8.3% in 2045, up from 7.7% in 2017[1], with the majority of cases being type 2 diabetes (T2D).[2-4] This increase is due, at least in part, to Japan's ageing population and changes in lifestyle factors, including diet and physical activity.[5,6] Impaired insulin secretion is considered an important characteristic among Japanese subjects with T2D compared with Caucasians, likely due to differences in body composition between these populations.[7,8]

Due to the progressive nature of T2D and associated deterioration of β-cell function, most patients will eventually require treatment intensification to maintain glycaemic targets. Japanese clinical practice guidelines emphasise treatment individualisation and intensification with oral antidiabetic drugs (OADs), glucagon-like peptide 1 receptor agonists (GLP-1RA) and basal or premix insulin.[9] Basal insulin is an effective therapy for reducing fasting plasma glucose (FPG) levels, but it is associated with considerable risk of hypoglycaemia and weight gain.[10-12] GLP-1RAs augment glucose-dependent insulin secretion, as well as preserving β-cell function, delaying gastric emptying, promoting weight loss and increasing insulin sensitivity.[13] The complementary actions of insulin and GLP-1RAs target multiple pathophysiological defects involved in T2D, and combining both therapies together can reduce HbA1c levels with lower risk of hypoglycaemia and weight gain compared with basal insulin alone.[14-17] However, this burdens subjects with two different treatment regimens, which may limit treatment adherence and intensification.[18,19]

Insulin degludec/liraglutide (IDegLira) is a fixed-ratio soluble combination of insulin degludec (degludec) and the GLP-1RA liraglutide (100 units [U] and 3.6 mg per mL, respectively), which allows once-daily administration of both active ingredients with a single injection. The efficacy and safety of

IDegLira has been investigated in a number of patient populations in the DUAL clinical trial programme.[20-28] Based on evidence from these trials, IDegLira received regulatory approval from the European Medicines Agency and the US Food and Drug Administration (FDA).[29,30]

The global DUAL I trial, which encompassed insulin-naïve subjects with T2D, demonstrated that treatment with IDegLira results in improved glycaemic control compared with each component administered separately, whilst mitigating the side effects associated with each, including the gastrointestinal side-effects associated with liraglutide.[20] This current study aimed to confirm the efficacy and safety of IDegLira compared with each of its components in Japanese subjects with T2D inadequately controlled on one OAD.

Materials and Methods

Study design and subjects

This 52-week, multi-centre, randomised, open-label, three-arm parallel-group trial investigated the efficacy and safety of IDegLira versus each of its components, degludec and liraglutide (**Figure 1**). The trial consisted of a 2-week screening period and a 52-week treatment period. Subjects were Japanese adults (age ≥20 years) with HbA1c levels of 53–97 mmol/mol (7.0–11.0%) and a body-mass index (BMI) of ≥20 kg/m^2, who had been diagnosed with T2D ≥6 months prior to screening and who were on stable therapy with one of six OAD types for a least 60 days prior to screening. Permitted OADs were aligned with Japanese clinical practice guidelines; alpha-glucosidase inhibitors, thiazolidinediones, sodium-glucose cotransporter-2 inhibitors, glinides, metformin or sulphonylureas.[9]

The protocol was approved by independent ethics committees or institutional review boards at all participating institutions and the study was performed in accordance with the Declaration of Helsinki

and ICH Good Clinical Practice guidelines. Written consent was obtained from all subjects before enrolment.

Treatment

IDegLira and degludec were administered once daily. Recommended starting doses were 10 dose steps of IDegLira (10 U degludec + 0.36 mg liraglutide) or 10 U of degludec. Doses were adjusted twice weekly in increments of ±2 U, aiming for a mean pre-breakfast self-measured blood glucose (SMBG; mean from three consecutive days) target range of 4.0–5.0 mmol/L (72–90 mg/dL; **Supplementary Table 1**). SMBG was assessed using a glucose meter calibrated to plasma equivalent values. The maximum dose of IDegLira was 50 dose steps, which delivers the maximum licenced liraglutide dose for diabetes (50 U degludec/1.8 mg liraglutide)[31]; there was no maximum dose for degludec.

Liraglutide was administered once daily. Liraglutide was initiated at 0.3 mg and increased by 0.3 mg each week over a 6-week period up to the maximum dose of 1.8 mg. Temporary dose reductions for <1 week were only allowed for safety reasons. OAD treatment continued unchanged at pre-trial doses; however, in case of safety concerns the dose could be reduced at the discretion of the investigator.

Randomisation and stratification

Subjects were randomised 1:1:1 via a centralised allocation via an interactive web response system to receive either IDegLira, degludec or liraglutide, each in combination with pre-trial OAD. Subjects were stratified by type of pre-trial OAD treatment to ensure an even distribution of each of the six OAD types across the three treatment arms.

Endpoints

The primary endpoint was change from baseline in HbA1c after 52 weeks of treatment for assessing superiority of IDegLira versus liraglutide and non-inferiority of IDegLira versus degludec. Secondary endpoints included: change from baseline in HbA1c after 52 weeks of treatment for assessing superiority of IDegLira versus degludec; percentage of subjects reaching HbA1c <53 mmol/mol (<7.0%) and ≤48 mmol/mol (≤6.5%) after 52 weeks of treatment; change from baseline in body weight after 52 weeks of treatment; fasting lipid profile and changes from baseline in FPG, nine-point SMBG profile, prandial plasma glucose increments (from before meal to 90 minutes after for breakfast, lunch and dinner) and blood pressure. Safety endpoints included number of treatment-emergent adverse events, number of treatment-emergent severe (defined according to the American Diabetes Association classification) or blood glucose (BG)-confirmed (plasma glucose <3.1 mmol/L [<56 mg/dL]) symptomatic hypoglycaemic episodes during 52 weeks of treatment, and pulse rate.

Statistical analyses

The main study objective was jointly confirming the noninferiority of IDegLira to insulin degludec alone with an upper 95% CI margin of 0.3%, and the superiority of IDegLira to liraglutide alone with a lower 95% CI margin of 0% (with respect to change in HbA1c at 26 weeks). The sample size was determined using a t-statistic under the assumption of a one-sided test with a type I error rate of 2.5% and a standard deviation of 1.0% for both the superiority and non-inferiority testing. For samples size calculations, the mean difference between treatments in change from baseline in HbA1c after 52 weeks was assumed to be –0.1% for non-inferiority and –0.3% for superiority testing. The per-protocol analysis set (assumed to be 85% of the randomised subject population) was used for the power calculation for non-inferiority, while the full analysis set was used for superiority. Based on these assumptions, a sample size of 807 subjects would provide a non-inferiority power of

98.9% and a superiority power of 93.5% giving an overall power for meeting the primary objective of 92.5%. A non-inferiority margin for the difference in the change from baseline in HbA1c after 52 weeks of treatment of 0.3% was selected based on existing FDA guidance, and is considered to be the minimal clinically significant change for HbA1c level.[32]

In order to ensure that the overall type-I error rate was not inflated, a hierarchical testing procedure was used. If the primary hypotheses were confirmed in change in HbA1c (i.e. IDegLira superiority to liraglutide and non-inferiority to degludec), the secondary confirmatory tests were performed for superiority of IDegLira versus degludec following a fixed sequence: 1. Change from baseline in body weight after 52 weeks of treatment; 2. Number of treatment-emergent severe or BG-confirmed hypoglycaemic episodes during 52 weeks of treatment; 3. Change in HbA1c after 52 weeks of treatment. Tests lower down the sequence in the hierarchy were only performed if the preceding test was statistically significant in favour of IDegLira.

Continuous efficacy endpoints including the primary endpoint were analysed separately using an analysis of covariance (ANCOVA) model including treatment, pre-trial OAD treatment as fixed factors and the baseline value of the parameter as a covariate. For the fasting lipid profile, the endpoint and baseline covariates were log-transformed before the analysis. Insulin dose was analysed using an ANCOVA model including the same fixed factors and baseline HbA1c as a covariate. Last observation carried forward was used to impute missing values for endpoints after 52 weeks of treatment. Attainment of glycaemic targets was analysed using a logistic regression model with treatment and pre-trial OAD treatment as fixed factors and baseline HbA1c as covariate.

Number of treatment emergent hypoglycaemic episodes was analysed using a negative binominal regression model with a log-link function and the logarithm of the time period in which a

hypoglycaemic episode was considered treatment emergent as offset, with treatment and pre-trial OAD treatment as fixed factors.

The robustness of the conclusions from the primary and confirmatory secondary analyses were assessed in various sensitivity analyses, including analysis of different analysis sets (per-protocol and completer) and using a mixed model for repeated measurements and a pattern mixture model approach mimicking an intention-to-treat scenario.

Results

Subjects

A total of 819 subjects were randomised and treated with either IDegLira (n=275), degludec (n=271) or liraglutide (n=273), all in combination with pre-trial OAD (**Supplementary Figure 1**). In total 54 subjects withdrew from the trial; 21 (7.6%) in the IDegLira group, 23 (8.5%) in the IDeg group and 10 (3.7%) in the liraglutide group. The number of withdrawals due to adverse events (AEs) was low and similar across treatment groups (8 subjects [2.9%] with IDegLira, 6 [2.2%] with degludec and 6 [2.2%] with liraglutide). Baseline characteristics were similar between treatment groups (**Table 1**).

Efficacy

After 52 weeks of treatment, mean HbA1c decreased from 69.6 mmol/mol (8.52%) to 43.1 mmol/mol (6.10%) with IDegLira, 69.7 mmol/mol (8.53%) to 50.1 mmol/mol (6.73%) with degludec and 67.4 mmol/mol (8.32%) to 47.7 mmol/mol (6.52%) with liraglutide (**Figure 2A**). Mean HbA1c was reduced to a significantly greater extent with IDegLira compared with liraglutide (–26.5 mmol/mol [−2.42%] vs –19.7 mmol/mol [−1.80%], estimated treatment difference [ETD], –5.30 mmol/mol [–6.58; –4.03]$_{95\%\ CI}$ {−0.48% [−0.60; −0.37]$_{95\%\ CI}$}, p<0.0001), confirming superiority for IDegLira versus liraglutide. Mean HbA1c was also significantly reduced with IDegLira compared with degludec (–26.5

mmol/mol [−2.42%] vs –19.6 mmol/mol [–1.80%], ETD –6.91 mmol/mol [–8.18; –5.64]$_{95\% CI}$, {−0.63% [−0.75; −0.52]$_{95\% CI}$}, p<0.0001) confirming non-inferiority of IDegLira versus degludec. Superiority of IDegLira versus degludec was confirmed as a part of confirmatory hierarchical testing procedure (−0.63% [−0.75; −0.52]$_{95\% CI}$, p<0.0001).

The level of glycaemic control demonstrated with IDegLira was supported by the secondary endpoint, achievement of predefined HbA1c targets (**Supplementary Figure 2**). The odds of achieving HbA1c <53 mmol/mol (<7.0%) and ≤48 mmol/mol (≤6.5%) were statistically significantly higher with IDegLira compared with either degludec (estimated odds ratio: <53 mmol/mol, 4.70 [2.82; 7.82]$_{95\% CI}$; ≤48 mmol/mol, 4.76 [3.12; 7.25]$_{95\% CI}$) or liraglutide (<53 mmol/mol, 3.90 [2.31; 6.59]$_{95\% CI}$; ≤48 mmol/mol, 2.94 [1.93; 4.50]$_{95\% CI}$; p<0.0001 for all).

Body weight

After 52 weeks, there was a significantly smaller increase in body weight with IDegLira (2.9 kg) versus degludec (4.1 kg; **Figure 2B**) with an ETD of −1.19 kg ([−1.80; −0.59]$_{95\% CI}$, p=0.0001 (p-value for superiority). The mean change from baseline in body weight was –1.0 kg with liraglutide versus 2.9 kg with IDegLira (**Figure 2B**), representing an ETD of 3.89 kg ([3.29; 4.49]$_{95\% CI}$, p<0.0001).

An exploratory analysis showed there was no significant interaction between background OAD therapy and treatment for the endpoint change in body weight; there was no effect of pre-trial OAD treatment on the differences between IDegLira and comparator.

Hypoglycaemic episodes

The cumulative incidence of severe or BG-confirmed hypoglycaemia is shown in **Figure 3**. After 52 weeks, rates of severe or BG-confirmed hypoglycaemia were 174.3, 331.9 and 4.8 events/100 patient-years of exposure [PYE] for IDegLira, degludec and liraglutide, respectively, with 38.5% of

IDegLira-treated subjects, 54.6% of degludec-treated subjects and 2.2% of liraglutide-treated subjects experiencing ≥1 event (**Table 2**). The treatment rate ratio (RR) of severe or BG-confirmed hypoglycaemic episodes was significantly lower for IDegLira versus degludec (0.48 [0.35; 0.68]$_{95\% CI}$, p<0.0001), confirming superiority, and significantly higher for IDegLira versus liraglutide (RR: 37.58 [19.80; 71.31]$_{95\% CI}$, p<0.0001). The percentage of subjects who experienced severe or BG-confirmed symptomatic hypoglycaemia was 19.3% (IDegLira), 29.5% (degludec) and 1.1% (liraglutide), with rates of 50.4, 138.3 and 1.5 events/100 PYE, respectively (**Table 2**).

Dose

Mean insulin dose during the first week were similar in the IDegLira (10.5 dose steps) and degludec (10.4 U) groups. After 52 weeks of treatment, the mean daily total insulin dose was significantly lower with IDegLira than degludec (27.7 vs 34.8 U, ETD, −7.01 U [−10.52; −3.50]$_{95\% CI}$, p<0.0001; **Supplementary Figure 3A**). Mean liraglutide doses were lower in the IDegLira group compared with the liraglutide group throughout the trial, and at week 52 were 1.0 mg and 1.8 mg, respectively (**Supplementary Figure 3B**). Of the subjects randomised to IDegLira, 17.1% (n=47) were on the maximum dose of 50 dose steps, and 74.5% of these subjects achieved the target of HbA1c <53 mmol/mol (<7.0%) at end of trial.

Fasting plasma glucose

FPG over time is displayed in **Figure 2C**. After 52 weeks of treatment, change from baseline in mean FPG was similar for IDegLira and degludec (–4.1 mmol/L [−73.6 mg/dL] and –4.0 mmol/L [−71.5 mg/dL], respectively) but greater for IDegLira versus liraglutide (–4.1 mmol/L [−73.6 mg/dL] vs –2.6 mmol/L [−47.1 mg/dL]).

Self-measured blood glucose

The mean nine-point SMBG profiles decreased across all groups throughout the trial (**Supplementary Figure 4**). After 52 weeks, SMBG profiles showed statistically significantly lower pre- and post-prandial glucose concentrations for IDegLira compared with degludec and liraglutide at all timepoints (except for pre-breakfast and at 4:00 a.m., which were similar between IDegLira and degludec).

After 52 weeks of treatment, the reduction from baseline in prandial glucose increments was statistically significantly greater with IDegLira compared with degludec for breakfast (ETD, −0.81 mmol/L [−1.24; −0.38]$_{95\% CI}$, −14.58 mg/dL [−22.27; −6.88]$_{95\% CI}$, p=0.0002), dinner (ETD, −0.66 mmol/L [−1.17; −0.15]$_{95\% CI}$, −11.94 mg/dL [−21.15; −2.73]$_{95\% CI}$, p=0.0111) and mean of all meals (ETD, −0.64 mmol/L [−0.96; −0.32]$_{95\% CI}$, −11.51 mg/dL [−17.26; −5.76]$_{95\% CI}$, p<0.0001), but not significant for lunch (ETD, −0.49 mmol/L [−1.02; 0.04]$_{95\% CI}$, −8.86 mg/dL [−18.44; 0.72]$_{95\% CI}$, p=0.0699). However, although a treatment difference for IDegLira compared with liraglutide was observed for breakfast (ETD, 0.48 mmol/L [0.06; 0.91]]$_{95\% CI}$, 8.70 mg/dL [1.03; 16.36]$_{95\% CI}$, p=0.0263), a significant difference was not observed for dinner (ETD, 0.16 mmol/L [−0.35; 0.67]$_{95\% CI}$, 2.84 mg/dL [−6.33; 12.02]$_{95\% CI}$, p=0.5430), lunch (ETD, 0.09 mmol/L [−0.44; 0.61]$_{95\% CI}$, 1.55 mg/dL [−7.97; 11.08]$_{95\% CI}$, p=0.7488) or mean of all meals (ETD, 0.24 mmol/L [−0.08; 0.56]$_{95\% CI}$, 4.33 mg/dL [−1.40; 10.06]$_{95\% CI}$, p=0.1385).

Vital signs

After 52 weeks, there was a statistically significant reduction in systolic blood pressure with IDegLira versus degludec (ETD, −2.05 mmHg [−4.02; −0.08]$_{95\% CI}$, p=0.0412). However, systolic blood pressure was significantly higher with IDegLira versus liraglutide (ETD, 2.88 mmHg [0.91; 4.85]$_{95\%CI}$, p=0.0042). There was no significant difference in diastolic blood pressure between IDegLira and either of its components. After 52 weeks of treatment, mean change in pulse rate was 3.9, 0.8 and 4.2 beats/min

with IDegLira, degludec and liraglutide, respectively; the difference between IDegLira and degludec was statistically significant (ETD IDegLira – degludec: 2.87 beats/min [1.43; 4.30]$_{95\% CI}$, p<0.0001), but a difference was not observed between IDegLira and liraglutide (ETD IDegLira – liraglutide: −0.43 beats/min [−1.86; 1.00]$_{95\% CI}$, p=0.5546).

Lipid profile

There was a statistically significant difference, in favour of IDegLira, for total cholesterol (versus degludec and liraglutide), low density lipoprotein cholesterol (versus degludec) and free fatty acids (versus liraglutide), and a statistically significant difference in high density lipoprotein cholesterol in favour of liraglutide versus IDegLira (**Supplementary Table 2**).

Adverse events

The percentage of subjects experiencing at least one AE was similar in each treatment group. The most frequently reported AEs were infections, with viral upper respiratory tract infection experienced by over one-third of subjects in each treatment group (**Table 2**). Gastrointestinal events were reported by 34.9%, 22.9% and 41.8% of subjects in the IDegLira, degludec and liraglutide groups, respectively. The overall rate of AEs per 100 PYE was similar between treatments groups. The majority of AEs were non-serious and judged unlikely to be related to trial products. In total, 24 subjects experienced 31 AEs that led to dose reductions during the trial; eight events in six subjects with IDegLira, 16 events in 13 subjects with degludec and seven events in five subjects with liraglutide. There were no confirmed events of thyroid disease. The event rate per 100 PYE of elevated lipase or amylase was 4.1, 7.4 and 0.0 with IDegLira, liraglutide and degludec, respectively. There were three events of elevated calcitonin (one with IDegLira and two with liraglutide).

Serious adverse events

The percentage of subjects experiencing at least one serious adverse event (SAE) was 6.2% in the IDegLira group, 4.8% in the degludec group and 5.1% in the liraglutide group. The majority of SAEs were considered as unlikely to be related to trial product (**Table 2**). The most frequently reported SAEs were in the cardiac disorder System Organ Class; three events in three subjects in the IDegLira and degludec groups and one event in the liraglutide group. All other SAEs were single events with no apparent difference in distribution between treatment groups. The event adjudication committee (EAC) classified five cardiovascular AEs (three with IDegLira and two with degludec) as major adverse cardiovascular events. There was one EAC-confirmed cardiovascular death in the IDegLira group, which was considered unlikely to be related to the trial product. The EAC also confirmed one event of mild acute pancreatitis in the IDegLira group, which was considered unlikely to be related to trial product, and 14 neoplasms (four with IDegLira including one malignant [local, gastric intestinal], three with degludec including one malignant [metastatic lung/bronchus] and seven with liraglutide including two malignant [local, breast and skin]).

Discussion

This open-label, treat-to-target trial investigated the efficacy and safety of IDegLira, in combination with an OAD, in Japanese subjects with T2D. After 52-weeks of treatment the superiority of IDegLira over both liraglutide and degludec in terms of reduction in HbA1c was confirmed. The improvement in HbA1c was reflected by the fact that a significantly higher percentage of subjects achieved HbA1c targets (<53 mmol/mol [<7.0%] or ≤48 mmol/mol [≤6.5%]) at end of trial with IDegLira compared with degludec or liraglutide, consistent with the results from the global DUAL I trial.[21] The –6.91 mmol/mol (–0.63%) HbA1c treatment difference with IDegLira versus degludec was achieved with a significantly lower daily total insulin dose with IDegLira (27.7 vs 34.8 U, respectively), showing the

contribution of the liraglutide component. Only approximately 17% of the subjects randomised to IDegLira reached the maximum allowed dose (50 dose steps) and the majority of these subjects (74.5%) achieved the target of HbA1c <53 mmol/mol (<7.0%) after 52 weeks.

There were significantly fewer severe or BG-confirmed hypoglycaemic episodes with IDegLira compared with degludec, reinforcing the contribution of the liraglutide component of IDegLira to the lower rate of hypoglycaemia seen with IDegLira in comparison with degludec in previous trials.[26] There was a significantly lower rate of severe or BG-confirmed hypoglycaemic episodes with liraglutide compared with IDegLira. This outcome was expected, due to the presence of the insulin component and the glucose-dependent mode of action of GLP-1 RAs.[33]

A significantly smaller increase in body weight was seen with IDegLira (2.9 kg) compared with degludec (4.1 kg), likely due to the weight-reducing effect of liraglutide.[20] This significant difference is in alignment with findings from the global trial programme.[20] The weight gain associated with IDegLira treatment is in contrast to the modest weight loss (−0.5 kg) observed with IDegLira in the global DUAL I trial,[20] which could be attributed to differences in background OAD therapy between the global DUAL I extension trial and this trial, and/or the difference in the relationship between BMI, insulin resistance and diabetes development in Japanese patients and Caucasian patients.[7,34-36]

When IDegLira was used, the mean daily doses of liraglutide and degludec were both lower compared with using the respective monotherapies after 52 weeks. In the liraglutide group, the daily dose reached the maximum licenced dose for diabetes of 1.8 mg by week 6, whereas in the IDegLira group, the actual daily liraglutide dose remained stable from week 9 onwards at approximately 1.0 mg. This demonstrates a clinical advantage of using the fixed-dose combination injection compared with the monotherapies alone.

There were no unexpected safety or tolerability issues identified with IDegLira, and the reported AEs were consistent with those of liraglutide or degludec.[37,38] Treatment with IDegLira also resulted in fewer gastrointestinal side effects compared with liraglutide treatment alone.

The DUAL I Japan trial aimed to compare the efficacy and safety of IDegLira with its components given alone in Japanese patients with T2D. Comparing IDegLira with the free combination of its components was beyond the scope of this trial and may be perceived as a study limitation. Nonetheless, co-administration of degludec and liraglutide within a single daily injection provides a simpler regimen than administering these components separately, and may help to overcome clinical inertia with respect to intensifying therapy.

In conclusion, in comparison with the individual components of IDegLira, the fixed-ratio combination offers Japanese subjects with T2D who have been on stable OAD therapy a simplified treatment regimen with the benefits of improved glycaemic control, a low risk of hypoglycaemia and less weight gain than insulin treatment alone.

Acknowledgements

The authors are grateful to the people who participated in this study, to Kenichiro Shimizu and Kristina Ranc (Novo Nordisk), for review of and input to the manuscript, and to Bridie Andrews, Victoria Atess and Richard McDonald of Watermeadow Medical (UK), an Ashfield Company, for providing medical writing and editorial support, which was funded by Novo Nordisk A/S, Søborg, Denmark in accordance with Good Publication Practice (GPP3) guidelines.

Funding statement

The trial was sponsored by Novo Nordisk A/S and is registered with ClinicalTrials.gov (NCT02607306).

Data sharing statement

The datasets generated during and/or analysed during the current study are available from the corresponding author on reasonable request.

Author contributions

All authors confirm that they meet the International Committee of Medical Journal Editors (ICJME) uniform requirements for authorship and that they have contributed to: critical analysis and interpretation of the data, drafting/critically revising the article and sharing in the final responsibility for the content of the manuscript and the decision to submit it for publication. KK was signatory investigator of this clinical trial, the guarantor of this work and, as such, had full access to all data in the study and takes responsibility for the integrity of the data.

Author disclosure information

KK has received honoraria or consulting fees from Astellas Pharma, AstraZeneca, Kowa Pharmaceutical, Mitsubishi Tanabe Pharma, MSD, Nippon Boehringer Ingelheim, Novo Nordisk Pharma, Sanwa Kagaku Kenkyusho, Dainippon Sumitomo Pharma, Taisho Toyama Pharmaceutical, Takeda.

EA has participated on advisory panels for Alcon, Astellas Pharma, Astra Zeneca, Eli Lilly, Kowa Pharmaceutical, Nippon Boehringer Ingelheim, Novo Nordisk Pharma, Sanofi and Terumo Corporation, has received honoraria for lectures from Astellas Pharma, MSD, Ono Pharmaceutical, Novo Nordisk Pharma and Sanofi, and scholarship grants from Astellas Pharma, Daiichi Sankyo,

Mitsubishi Tanabe Pharma, Nippon Boehringer Ingelheim, Novo Nordisk Pharma, Ono Pharmaceutical, Sanofi, Shionogi, Sumitomo Dainippon Pharma and Takeda Pharmaceutical.

YT has participated on advisory panels for Kowa Pharmaceutical, Novo Nordisk Pharma, and Terumo Corporation, has received honoraria for lectures from Astellas Pharma, MSD, Ono Pharmaceutical, Novo Nordisk Pharma, Sanofi and Takeda Pharmaceutical, and scholarship grants from Astellas Pharma, Eli Lilly, Daiichi Sankyo, Mitsubishi Tanabe Pharma, Nippon Boehringer Ingelheim, Novo Nordisk Pharma, Ono Pharmaceutical, Sanofi, Shionogi, Sumitomo Dainippon Pharma and Takeda Pharmaceutical.

BRA, TN and MR are employees and shareholders in Novo Nordisk.

NI has acted as a speaker for MSD, ARKRAY, Inc., Astellas Pharma, Kissei , Sanofi, Novartis Pharma, Novo Nordisk Pharma, Bayer, Kowa Pharma, Ono Pharma, Kyowa Hakko Kirin, Sumitomo Dainippon Pharma, Daiichi Sankyo, Eli Lilly Japan, Nippon Boehringer Ingelheim, Takeda Pharma, Mitsubishi Tanabe Pharma, Medtronic Japan, Taisho Toyama Pharma, Pfizer Japan, FUJIFILM Pharma, Saishin-igaku, Toyooka Hospital, Terumo, Olympus, Sunstar Foundation, Japan Tobacco, ILSI Japan, University of Occupational and Environmental Health, Japanese Red Cross Wakayama Medical Center, AstraZeneca, Tsumura, Chugai Pharma, Wakayama Med. Univ., Hokkaido Univ., Boehringer Ingelheim, MSD Life Science Foundation and receiving grants from Shionogi, Pfizer Japan, Eli Lilly Japan, Tsumura, Taisho Toyama Pharma, Novo Nordisk Pharma, The Japan China Medical Association, Teijin Pharma.

References

1. Federation ID. IDF Atlas, 8th Edition: Japan country report. http://reports.instantatlas.com/report/view/846e76122b5f476fa6ef09471965aedd/JPN. Accessed October 2018.
2. Morimoto A, Nishimura R, Tamija N. Trends in the epidemiology of patients with diabetes in Japan. *Japan Med Assoc J* 2010;53:36–40.
3. Kawaski E MN, Eguchi K. Type 1 diabetes in Japan. *Diabetologia* 2006;49:828–836.
4. Forouhi NG, Wareham NJ. Epidemiology of diabetes. *Medicine (Abingdon)* 2014;42:698-702.
5. Chan JC, Malik V, Jia W, et al. Diabetes in Asia: epidemiology, risk factors, and pathophysiology. *JAMA* 2009;301:2129-2140.
6. Charvat H, Goto A, Goto M, et al. Impact of population aging on trends in diabetes prevalence: A meta-regression analysis of 160,000 Japanese adults. *J Diabetes Investig* 2015;6:533-542.
7. Moller JB, Pedersen M, Tanaka H, et al. Body composition is the main determinant for the difference in type 2 diabetes pathophysiology between Japanese and Caucasians. *Diabetes Care* 2014;37:796-804.
8. Kuroe A, Fukushima M, Usami M, et al. Impaired beta-cell function and insulin sensitivity in Japanese subjects with normal glucose tolerance. *Diabetes Res Clin Pract* 2003;59:71-77.
9. Haneda M, Noda M, Origasa H, et al. Japanese Clinical Practice Guideline for Diabetes 2016. *J Diabetes Investig* 2018;3:657–697.
10. DeFronzo RA, Eldor R, Abdul-Ghani M. Pathophysiologic approach to therapy in patients with newly diagnosed type 2 diabetes. *Diabetes Care* 2013;36 Suppl 2:S127-138.
11. Davies MJ, D'Alessio DA, Fradkin J, et al. Management of hyperglycemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). *Diabetes Care* 2018;41:2669-2701.
12. 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes—2019. *Diabetes Care* 2019;42:S90-S102.
13. Nauck MA. Unraveling the science of incretin biology. *Am J Med* 2009;122:S3-s10.
14. Buse JB, Bergenstal RM, Glass LC, et al. Use of twice-daily exenatide in basal insulin-treated patients with type 2 diabetes: a randomized, controlled trial. *Ann Intern Med* 2011;154:103–112.
15. Riddle MC, Aronson R, Home P, et al. Adding once-daily lixisenatide for type 2 diabetes inadequately controlled by established basal insulin: a 24-week, randomized, placebo-controlled comparison (GetGoal-L). *Diabetes Care* 2013;36:2489–2496.
16. Riddle MC, Forst T, Aronson R, et al. Adding once-daily lixisenatide for type 2 diabetes inadequately controlled with newly initiated and continuously titrated basal insulin glargine: a 24-week, randomized, placebo-controlled study (GetGoal-Duo 1). *Diabetes Care* 2013;36:2497–2503.
17. Ahmann A, Rodbard HW, Rosenstock J, et al. Efficacy and safety of liraglutide versus placebo added to basal insulin analogues (with or without metformin) in patients with type 2 diabetes: a randomized, placebo-controlled trial. *Diabetes Obes Metab* 2015;17:1056–1064.
18. Russell-Jones D, Pouwer F, Khunti K. Identification of barriers to insulin therapy and approaches to overcoming them. *Diabetes Obes Metab* 2018;20:488-496.

19. Donnelly LA, Morris AD, Evans JM, collaboration DM. Adherence to insulin and its association with glycaemic control in patients with type 2 diabetes. *QJM* 2007;100:345–350.
20. Gough SC, Bode BW, Woo VC, et al. One-year efficacy and safety of a fixed combination of insulin degludec and liraglutide in patients with type 2 diabetes: results of a 26-week extension to a 26-week main trial. *Diabetes Obes Metab* 2015;17:965–973.
21. Gough SC, Bode B, Woo V, et al. Efficacy and safety of a fixed-ratio combination of insulin degludec and liraglutide (IDegLira) compared with its components given alone: results of a phase 3, open-label, randomised, 26-week, treat-to-target trial in insulin-naive patients with type 2 diabetes. *Lancet Diabetes Endocrinol* 2014;2:885–893.
22. Billings LK, Doshi A, Gouet D, et al. Efficacy and safety of IDegLira versus basal-bolus insulin therapy in patients with type 2 diabetes uncontrolled on metformin and basal insulin: The DUAL VII randomized clinical trial. *Diabetes Care* 2018;41:1009–1016.
23. Lingvay I, Harris S, Jaeckel E, Chandarana K, Ranthe MF, Jodar E. Insulin degludec/liraglutide (IDegLira) was effective across a range of dysglycaemia and body mass index categories in the DUAL V randomized trial. *Diabetes Obes Metab* 2018;20:200-205.
24. Harris SB, Kocsis G, Prager R, et al. Safety and efficacy of IDegLira titrated once weekly versus twice weekly in patients with type 2 diabetes uncontrolled on oral antidiabetic drugs: DUAL VI randomized clinical trial. *Diabetes Obes Metab* 2017;19:858–865.
25. Linjawi S, Bode BW, Chaykin LB, et al. The efficacy of IDegLira (insulin degludec/liraglutide combination) in adults with type 2 diabetes inadequately controlled with a GLP-1 receptor agonist and oral therapy: DUAL III randomized clinical trial. *Diabetes Ther* 2017;8:101–114.
26. Buse JB, Vilsboll T, Thurman J, et al. Contribution of liraglutide in the fixed-ratio combination of insulin degludec and liraglutide (IDegLira). *Diabetes Care* 2014;37:2926-2933.
27. Rodbard HW, Bode BW, Harris SB, et al. Safety and efficacy of IDegLira added to sulphonylureas alone or sulphonylureas and metformin in insulin-naïve people with Type 2 diabetes: the DUAL IV trial. *Diabet Med* 2017;34:189–196.
28. Philis-Tsimikas A, Billings LK, Busch R, et al. Superior Efficacy of Insulin Degludec/Liraglutide versus Insulin Glargine U100 as Add-on to Sodium-Glucose Co-Transporter-2 Inhibitor Therapy: a Randomized Clinical Trial in Patients with Uncontrolled Type 2 Diabetes. *Diabetes Obes Metab* 2019;6:1399–1408.
29. Novo Nordisk. Xultophy® summary of product characteristics. 2018. https://www.medicines.org.uk/emc/product/3469. Accessed July 2018.
30. Novo Nordisk. Xultophy® 100/3.6 Prescribing Information (PI). 2016. https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/208583s000lbl.pdf. Accessed November 2018.
31. Novo Nordisk. Victoza® Summary of Product Characteristics. 2017. https://www.medicines.org.uk/emc/product/6585/smpc. Accessed July 2018.
32. US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research. Guidance for Industry: Diabetes Mellitus - evaluating cardiovascular risk in new antidiabetic therapies to treat type 2 diabetes. 2008. https://www.fda.gov/downloads/Drugs/Guidances/ucm071627.pdf.
33. Norwood P, Chen R, Jaeckel E, et al. Rates of hypoglycaemia are lower in patients treated with insulin degludec/liraglutide (IDegLira) than with IDeg or insulin glargine, regardless of the hypoglycaemia definition used. *Diabetes Obes Metab* 2017;19:1562-1569.

34. Furukawa Y, Tamura Y, Takeno K, et al. Impaired peripheral insulin sensitivity in non-obese Japanese patients with type 2 diabetes mellitus and fatty liver. *J Diabetes Investig* 2017;3:529–535.
35. Ito D, Iuchi T, Kurihara S, Inoue I, Katayama S, Inukai K. Efficacy and Clinical Characteristics of Liraglutide in Japanese Patients With Type 2 Diabetes. *J Clin Med Res* 2015;7:694-699.
36. Seino Y, Rasmussen MF, Zdravkovic M, Kaku K. Dose-dependent improvement in glycemia with once-daily liraglutide without hypoglycemia or weight gain: A double-blind, randomized, controlled trial in Japanese patients with type 2 diabetes. *Diabetes Res Clin Pract* 2008;81:161-168.
37. Keating GM. Insulin degludec and insulin degludec/insulin aspart: a review of their use in the management of diabetes mellitus. *Drugs* 2013;73:575–593.
38. Bode B. An overview of the pharmacokinetics, efficacy and safety of liraglutide. *Diabetes Res Clin Pract* 2012;97:27–42.

Tables and figures

Table 1: Baseline characteristics of subjects

	IDegLira (N=275)	Degludec (N=271)	Liraglutide (N=273)
Age, years			
Mean (SD)	56.9 (10.2)	57.8 (9.9)	56.8 (10.1)
Median (Min; Max)	57.0 (29.0; 81.0)	59.0 (22.0; 80.0)	57.0 (25.0; 79.0)
Sex, n (%)			
Female	81 (29.5)	76 (28.0)	81 (29.7)
Male	194 (70.5)	195 (72.0)	192 (70.3)
Body weight, kg			
Mean (SD)	70.7 (12.4)	72.6 (14.5)	72.2 (15.0)
Median (Min; Max)	68.7 (44.1; 113.3)	70.5 (44.8; 161.8)	70.4 (42.3; 142.4)
BMI, kg/m^2			

Mean (SD) Median (Min; Max)	26.1 (3.7) 25.5 (19.9; 36.8)	26.6 (4.8) 25.5 (19.6; 56.0)	26.5 (4.5) 25.8 (19.8; 45.5)
HbA1c, mmol/mol Mean (SD) Median (Min; Max)	 69.6 (12.2) 67.2 (50.8; 98.9)	 69.7 (11.5) 67.2 (51.9; 101.1)	 67.4 (10.8) 63.9 (49.7; 101.1)
HbA1c, % Mean (SD) Median (Min; Max)	 8.5 (1.1) 8.3 (6.8; 11.2)	 8.5 (1.1) 8.3 (6.9; 11.4)	 8.3 (1.0) 8.0 (6.7; 11.4)
Fasting plasma glucose, mmol/L Mean (SD) Median (Min; Max)	 9.9 (2.4) 9.4 (5.1; 17.6)	 10.0 (2.3) 9.6 (5.5; 17.0)	 9.7 (2.2)[†] 9.3 (5.1; 19.3)[†]
Fasting C-peptide, nmol/L Geometric mean (CV%) Median (Min; Max)	 0.49 (42.8) 0.50 (0.20; 1.68)	 0.51 (47.1) 0.49 (0.12; 2.19)	 0.50 (43.0)[†] 0.49 (0.16; 1.36)[†]
Fasting plasma glucose, mg/dL Mean (SD) Median (Min; Max)	 178.7 (43.0) 170.0 (92.0; 318.0)	 179.9 (42.3) 173.0 (99.0; 307.0)	 175.4 (39.8)[†] 168.0 (92.0; 347.0)[†]
Duration of diabetes, years Mean (SD) Median (Min; Max)	 9.2 (6.2) 8.1 (0.6; 45.3)	 9.7 (6.0) 8.7 (0.5; 30.7)	 9.4 (5.9) 8.4 (0.8; 33.9)
OAD use at screening, n (%)			

Metformin	47 (17.1)	46 (17.0)	47 (17.2)
Alpha-glucosidase inhibitor	41 (14.9)	40 (14.8)	41 (15.0)
Thiazolidinedione	43 (15.6)	43 (15.9)	42 (15.4)
Sulphonylurea	43 (15.6)	42 (15.5)	42 (15.4)
SGLT2i	61 (22.2)	61 (22.5)	61 (22.3)
Glinide	40 (14.5)	39 (14.4)	40 (14.7)

[†]N=272.

BMI, body mass index; CV, coefficient of variation; OAD, oral anti-diabetic drug; SGLT2i, sodium-glucose co-transporter 2 inhibitor.

Table 2: Adverse events

Event	IDegLira (N=275)				Degludec (N=271)				Liraglutide (N=273)			
	n	%	E	R	n	%	E	R	n	%	E	R
AE	229	83.3	873	325.7	216	79.7	829	316.6	229	83.9	885	325.6
AE possibly or probably related to treatment	88	32.0	152	56.7	55	20.3	84	32.1	108	39.6	210	77.3
Most frequent AE (≥5% of subjects)												
Infections and infestations												
Viral upper respiratory tract infection	106	38.5	166	61.9	91	33.6	161	61.5	94	34.4	155	57.0
Pharyngitis	11	4.0	13	4.9	15	5.5	18	6.9	9	3.3	9	3.3
Influenza	15	5.5	15	5.6	9	3.3	9	3.4	9	3.3	9	3.3
Gastrointestinal disorders												
Constipation	27	9.8	28	10.4	12	4.4	12	4.6	38	13.9	42	15.5

Diarrhoea	15	5.5	20	7.5	12	4.4	14	5.3	24	8.8	31	11.4
Nausea	9	3.3	13	4.9	5	1.8	7	2.7	23	8.4	30	11.0
Investigations												
Weight increased	4	1.5	4	1.5	19	7.0	19	7.3	1	0.4	1	0.4
Lipase increased	6	2.2	8	3.0	0	-	-	-	15	5.5	15	5.5
Eye disorders												
Diabetic retinopathy	17	6.2	17	6.3	12	4.4	14	5.3	11	4.0	11	4.0
Skin and subcutaneous tissue disorders												
Eczema	16	5.8	18	6.7	6	2.2	6	2.3	9	3.3	10	3.7
Nervous system disorders												
Headache	7	2.5	11	4.1	7	2.6	12	4.6	15	5.5	17	6.3
SAE	17	6.2	18	6.7	13	4.8	16	6.1	14	5.1	14	5.2
SAE possibly or probably related to trial product	2	0.7	2	0.7	1	0.4	1	0.4	1	0.4	1	0.4

Severe or BG-confirmed symptomatic hypoglycaemia	53	19.3	135	50.4	80	29.5	362	138.3	3	1.1	4	1.5
Severe or BG-confirmed hypoglycaemia	106	38.5	467	174.3	148	54.6	869	331.9	6	2.2	13	4.8

%, percentage of subjects with one or more events; AE, adverse event; BG, blood glucose; E, number of adverse events; n, number of subjects with one or more events; R, rate (number of AEs divided by subject years of exposure [365.25 days] multiplied by 100); SAE, serious adverse event. Treatment emergent: onset date on or after the first day of exposure to randomised treatment and no later than 7 days after the last day of randomised treatment.

Figures

Figure 1: Trial design

*Maximum dose of liraglutide was 1.8 mg, double the maximum approved dose in Japan of 0.9 mg.

α-GI, alpha-glucosidase inhibitor; IDegLira, insulin degludec/liraglutide; Lira, liraglutide; OAD, oral antidiabetic drug; SGLT2i, sodium-glucose co-transporter 2 inhibitors; SU, sulphonylurea; TZD, thiazolidinedione.

Figure 2: Mean HbA1c (A), body weight (B) and fasting plasma glucose (C) over 52 weeks

Full analysis set. Missing values are imputed using last observation carried forward. Error bars: represent standard error.

EOT, end of trial; FPG, fasting plasma glucose; IDegLira, insulin degludec/liraglutide.

Figure 3: Cumulative incidence of severe or BG-confirmed hypoglycaemia (with or without symptoms)

Safety analysis set. Observed data. Severe or BG-confirmed: An episode that is severe according to the ADA classification or BG-confirmed by a plasma glucose value <3.1 mmol/L (<56 mg/dL) with or without symptoms consistent with hypoglycaemia.

ADA, American Diabetes Association; BG, blood glucose; IDegLira, insulin degludec/liraglutide.